The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 12, 2017
Filed:
Jun. 15, 2016
Applicant:
Tetralogic Birinapant Uk Ltd., Birmingham, GB;
Inventors:
Stephen M. Condon, Glenmoore, PA (US);
Matthew G. Laporte, Honeybrook, PA (US);
Yijun Deng, Dresher, PA (US);
Susan R. Rippin, Wilmington, DE (US);
Assignee:
TetraLogic Birinapant UK Ltd., Birmingham, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); C07D 207/08 (2006.01); A61K 31/395 (2006.01); C07D 207/09 (2006.01); C07D 207/10 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 405/06 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 491/04 (2006.01); C07D 491/14 (2006.01); C07K 5/062 (2006.01); C07D 491/147 (2006.01); C07D 207/12 (2006.01); C07D 417/14 (2006.01); C07D 498/16 (2006.01); C07D 491/18 (2006.01);
U.S. Cl.
CPC ...
C07D 207/08 (2013.01); A61K 31/395 (2013.01); C07D 207/09 (2013.01); C07D 207/10 (2013.01); C07D 207/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 417/14 (2013.01); C07D 491/04 (2013.01); C07D 491/14 (2013.01); C07D 491/147 (2013.01); C07D 491/18 (2013.01); C07D 498/16 (2013.01); C07K 5/06026 (2013.01); C07K 5/06034 (2013.01);
Abstract
IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kof less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.